Human tumor cells

Human tumor cells are host-derived cells that have undergone genetic and epigenetic transformations resulting in unregulated growth and the potential for tissue invasion and metastasis [6]. These cells are characterized by several biological hallmarks, including the ability to sustain proliferative signaling, evade growth suppressors, and resist programmed cell death (apoptosis) [6, 12, 14]. In the context of drug development and screening, human tumor cells are often treated as a 'target' in phenotypic assays to evaluate the cytotoxic or cytostatic potential of new compounds [7, 9]. However, from a strictly pharmacological perspective, 'Human tumor cells' is considered an overly broad or incorrect designation for a molecular target, as it represents a complex biological population rather than a specific protein or receptor [7]. Therapeutic intervention against these cells involves diverse strategies, ranging from conventional chemotherapy that targets cell division to precision medicine that inhibits specific molecular drivers like mutated kinases or cell-surface receptors [10, 15]. A major challenge in treating human tumor cells is their inherent heterogeneity and ability to evolve, which frequently leads to the emergence of therapeutic resistance [8, 19].

Other names

Malignant cellsCancer cellsNeoplastic cellsHuman cancer cells

Drugs targeting human tumor cells primarily act via non-specific cytotoxicity, induction of DNA damage, inhibition of mitosis, or interference with metabolic processes; targeted therapies specifically inhibit oncogenic signaling pathways within the cells [6, 19].